Akero Therapeutics Inc Asset Resilience Ratio
Akero Therapeutics Inc asset resilience ratio. Akero Therapeutics Inc (AKRO) has an Asset Resilience Ratio of 55.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Akero Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Akero Therapeutics Inc (2018–2024)
Asset resilience ratio of Akero Therapeutics Inc from 2018 to 2024. This chart shows how Akero Therapeutics Inc's Asset Resilience Ratio has changed over time. Read how much debt does Akero Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Akero Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AKRO total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $561.79 Million | 55.87% |
| Total Liquid Assets | $561.79 Million | 55.87% |
Asset Resilience Insights
- Very High Liquidity: Akero Therapeutics Inc maintains exceptional liquid asset reserves at 55.87% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Akero Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Akero Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Akero Therapeutics Inc Asset Resilience Ratio by Year (2018–2024)
Akero Therapeutics Inc asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for Akero Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 48.78% | $402.84 Million | $825.89 Million | -5.65pp |
| 2023-12-31 | 54.42% | $315.80 Million | $580.27 Million | +25.91pp |
| 2022-12-31 | 28.52% | $101.68 Million | $356.57 Million | +9.20pp |
| 2021-12-31 | 19.32% | $37.77 Million | $195.55 Million | -10.37pp |
| 2020-12-31 | 29.69% | $81.14 Million | $273.34 Million | -22.16pp |
| 2019-12-31 | 51.85% | $71.61 Million | $138.12 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $77.15 Million | -- |
About Akero Therapeutics Inc
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic… Read more